SCHEMBL25003827

SCHEMBL25003827

NNC(=O)c1ccnc(-c2ccc(OC3CCCC3)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 3/20 0.46
▸ LMNA P02545 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PARP10 Q53GL7 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TYK2 P29597 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ XDH P47989 1/20 0.40
▸ GRM5 P41594 3/20 0.40
▸ MAP4K4 O95819 1/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ LNPEP Q9UIQ6 1/20 0.38
▸ TNK2 Q07912 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25002923 0.84 FDPS (0.44) FDPSLMNAALDH1A1NPC1RAB9A
SCHEMBL25003161 0.83 FDPS (0.58) FDPSLMNAALDH1A1NPC1RAB9A
SCHEMBL25003826 0.80 CA1 (0.54) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL25003126 0.79 ALDH1A1 (0.51) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL25003144 0.79 KMO (0.51) FDPSLMNAALDH1A1NPC1RAB9A
SCHEMBL25003802 0.79 FDPS (0.48) FDPSLMNAALDH1A1NPC1RAB9A
SCHEMBL25003134 0.77 NPC1 (0.51) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL25003153 0.77 KMT2A (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL25003794 0.77 PLK1 (0.49) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27237488 0.76 HDAC6 (0.47) LMNAALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023010192-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 — — WO disclosed
Send feedback